Dominantly Inherited Alzheimer Network Trials Unit – (DIAN-TU) study
The Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) Study enables researchers around the world to identify changes in individuals who carry a gene mutation (Presenilin1, Presenilin2 or APP) known to cause dominantly inherited Alzheimer’s Disease (DIAD).
Alzheimer’s disease is defined by the presence of abnormal accumulations of amyloid protein (plaques) and tau protein (tangles) in the brain. The DIAN-TU study tests whether study drug/s provide a clinical benefit by slowing the onset or the worsening of the disease.
Beta amyloid is a protein that accumulates in the brain of people with Alzheimer’s disease. Although we do not understand exactly what causes Alzheimer’s disease, the abnormal accumulation of beta amyloid protein in the brain is thought to play an important role in the symptoms of Alzheimer’s disease.
This study collects results of brain scans, blood and spinal fluid tests (also called ‘biomarkers’), as well as tests of memory and thinking. The idea is to find if a study drug has favourable effects on these tests as it may prevent or delay the symptoms of Alzheimer’s disease.
- Biomarker collection
- Cognitive and clinical assessments
- Imaging (PET, MRI)
- Beverley Clinch
- Dr Therese Thornton